Register entry
Boehringer Ingelheim Biopharmaceuticals China Ltd
Data as of · How to read this entry
- Registered sites
- 3
- Active NDC listings
- 127
- Labeller names
- 4
- Live patents
- 551
- Exclusivities
- 9
- Countries
- 2
- Base
- Germany
Authorisation
Registered operations
Analytical testing3Active ingredient (API) manufacture3Labelling3Finished drug manufacture3Packaging3
Sites
Registered establishments
3| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (Branch Plant)Registrant: Boehringer Ingelheim Biopharmaceuticals China Ltd | 257, Lishizhen Road, Pilot Free Trade Zone, Shanghai, -Select State- 201203, China (CHN) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3015009021699374574 |
| Boehringer Ingelheim Pharma GmbH and Co. KG | Birkendorfer Strasse 65, Biberach an der Riss, 88397, Germany (DEU) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3002806518340700520 |
| Boehringer Ingelheim Pharma GmbH and Co. KG | Binger Strasse 173, Ingelheim am Rhein, Rhineland-Palatinate 55216, Germany (DEU) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3002806556551147440 |
Catalogue
Drug listings by form and route
127127 active NDC listings: 65 human prescription drug, 32 drug for further processing, 30 bulk ingredient. By marketing category: NDA 49, DRUG FOR FURTHER PROCESSING 32, BULK INGREDIENT 30, BLA 16.
| Dosage form | NDCs |
|---|---|
| powder | 21 |
| solution | 18 |
| tablet | 18 |
| tablet, film coated | 14 |
| kit | 12 |
| liquid | 8 |
| tablet, extended release | 8 |
| pellet | 7 |
| capsule | 6 |
| spray, metered | 5 |
| injection | 4 |
| powder, for solution | 2 |
| tablet, film coated, extended release | 2 |
| aerosol, metered | 1 |
| granule | 1 |
| Route | NDCs |
|---|---|
| oral | 43 |
| respiratory (inhalation) | 7 |
| intravenous | 4 |
| Labeller name on the listing | NDCs |
|---|---|
| boehringer ingelheim pharmaceuticals, inc. | 62 |
| boehringer ingelheim pharma gmbh and co. kg | 60 |
| boehringer ingelheim pharmaceuticals inc. | 3 |
| boehringer ingelheim biopharmaceuticals (china) ltd. | 2 |
Exclusivity
Patents and exclusivities
551| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9539258 | GILOTRIFafatinib dimaleate | use | Nov 2026 |
| 12171739 | HERNEXEOSzongertinib | substance, product | Nov 2026 |
| 7727984 | STIOLTO RESPIMAT, STRIVERDI RESPIMATolodaterol hydrochloride; olodaterol hydrochloride; tiotropium bromide | substance | Jan 2027 |
| 7396341*PED | SPIRIVA RESPIMAT, STIOLTO RESPIMATolodaterol hydrochloride; tiotropium bromide; tiotropium bromide | use | Apr 2027 |
| 7713938 | GLYXAMBI, JARDIANCE, SYNJARDY, SYNJARDY XR, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride; empagliflozin; metformin hydrochloride | substance, product | Apr 2027 |
| 11033552 | GLYXAMBI, TRADJENTAempagliflozin; linagliptin; linagliptin | product | May 2027 |
| 12178819 | GLYXAMBI, TRADJENTAempagliflozin; linagliptin; linagliptin | product | May 2027 |
| 9539258*PED | GILOTRIFafatinib dimaleate | use | May 2027 |
| 9027967*PED | SPIRIVA RESPIMATtiotropium bromide | use | Sept 2027 |
| 7713938*PED | GLYXAMBI, JARDIANCE, SYNJARDY, SYNJARDY XR, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride; empagliflozin; metformin hydrochloride | use | Oct 2027 |
| 11033552*PED | GLYXAMBI, TRADJENTAempagliflozin; linagliptin; linagliptin | use | Nov 2027 |
| 8673927*PED | GLYXAMBI, JENTADUETO, JENTADUETO XR, TRADJENTAempagliflozin; linagliptin; linagliptin; linagliptin; metformin hydrochloride | use | Nov 2027 |
| 9173859*PED | JENTADUETO XRlinagliptin; metformin hydrochloride | use | Nov 2027 |
| 7695734 | MIRAPEX ERpramipexole dihydrochloride | product | Apr 2028 |
| 7579449 | GLYXAMBI, JARDIANCE, SYNJARDY, SYNJARDY XR, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride; empagliflozin; metformin hydrochloride | substance | Aug 2028 |
| 7837235*PED | SPIRIVA RESPIMAT, STIOLTO RESPIMATolodaterol hydrochloride; tiotropium bromide; tiotropium bromide | use | Sept 2028 |
| 7579449*PED | GLYXAMBI, JARDIANCE, SYNJARDY, SYNJARDY XR, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride; empagliflozin; metformin hydrochloride | use | Feb 2029 |
| 8460704 | VIRAMUNE XRnevirapine | use | Mar 2029 |
| 10022379 | JENTADUETO, JENTADUETO XR, TRIJARDY XRempagliflozin; linagliptin; metformin hydrochloride; linagliptin; metformin hydrochloride | product | Apr 2029 |
| 10973827 | JENTADUETOlinagliptin; metformin hydrochloride | product | Apr 2029 |
| 12678442 | JENTADUETO, JENTADUETO XR, TRIJARDY XRempagliflozin; linagliptin; metformin hydrochloride; linagliptin; metformin hydrochloride | product | Apr 2029 |
| 9415016 | JENTADUETO, JENTADUETO XR, TRIJARDY XRempagliflozin; linagliptin; metformin hydrochloride; linagliptin; metformin hydrochloride | product | Apr 2029 |
| 10105323 | OFEVnintedanib esylate | product | Jun 2029 |
| 9907756 | OFEVnintedanib esylate | product | Jun 2029 |
| 10034877 | TRADJENTAlinagliptin | use | Aug 2029 |
| 9486526 | TRADJENTAlinagliptin | use | Aug 2029 |
| 8679533 | MIRAPEX ERpramipexole dihydrochloride | product | Sept 2029 |
| 10022379*PED | JENTADUETO, JENTADUETO XRlinagliptin; metformin hydrochloride | use | Oct 2029 |
| 10973827*PED | JENTADUETOlinagliptin; metformin hydrochloride | use | Oct 2029 |
| 12678442*PED | TRIJARDY XRempagliflozin; linagliptin; metformin hydrochloride | use | Oct 2029 |
| 9415016*PED | JENTADUETO, JENTADUETO XRlinagliptin; metformin hydrochloride | use | Oct 2029 |
| 8426586 | GILOTRIFafatinib dimaleate | substance | Oct 2029 |
| 8551957 | GLYXAMBI, JARDIANCE, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride | product | Oct 2029 |
| 8754073 | JASCAYDnerandomilast | substance, product | Nov 2029 |
| 10105323*PED | OFEVnintedanib esylate | use | Dec 2029 |
| 9907756*PED | OFEVnintedanib esylate | use | Dec 2029 |
| 8545884 | GILOTRIFafatinib dimaleate | product | Dec 2029 |
| 10034877*PED | TRADJENTAlinagliptin | use | Feb 2030 |
| 9486526*PED | TRADJENTAlinagliptin | use | Feb 2030 |
| 12115179 | GLYXAMBI, JARDIANCE, SYNJARDY, SYNJARDY XR, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride; empagliflozin; metformin hydrochloride | use | Feb 2030 |
| 11911388 | JENTADUETO, JENTADUETO XR, TRADJENTAlinagliptin; linagliptin; metformin hydrochloride | use | Apr 2030 |
| 8426586*PED | GILOTRIFafatinib dimaleate | use | Apr 2030 |
| 8551957*PED | GLYXAMBI, JARDIANCE, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride | use | Apr 2030 |
| 9155705 | JENTADUETO, JENTADUETO XR, TRIJARDY XRempagliflozin; linagliptin; metformin hydrochloride; linagliptin; metformin hydrochloride | product | May 2030 |
| 8846695 | JENTADUETOlinagliptin; metformin hydrochloride | use | Jun 2030 |
| 10406172 | TRIJARDY XRempagliflozin; linagliptin; metformin hydrochloride | product | Jun 2030 |
| 8545884*PED | GILOTRIFafatinib dimaleate | use | Jun 2030 |
| 10004743 | GILOTRIFafatinib dimaleate | product | Jul 2030 |
| 12115179*PED | GLYXAMBI, JARDIANCE, SYNJARDY, SYNJARDY XR, TRIJARDY XRempagliflozin; empagliflozin; linagliptin; empagliflozin; linagliptin; metformin hydrochloride; empagliflozin; metformin hydrochloride | use | Aug 2030 |
| 10610489 | SYNJARDYempagliflozin; metformin hydrochloride | product | Sept 2030 |
| 9155705*PED | JENTADUETO, JENTADUETO XRlinagliptin; metformin hydrochloride | use | Nov 2030 |
| 8846695*PED | JENTADUETO, TRADJENTAlinagliptin; linagliptin; metformin hydrochloride | use | Dec 2030 |
| 10004743*PED | GILOTRIFafatinib dimaleate | use | Jan 2031 |
| 9034822 | PRADAXAdabigatran etexilate mesylate | use | Jan 2031 |
| 8853156 | TRADJENTAlinagliptin | product | Mar 2031 |
| 10610489*PED | SYNJARDYempagliflozin; metformin hydrochloride | use | Mar 2031 |
| 8733341*PED | SPIRIVA RESPIMATtiotropium bromide | use | Apr 2031 |
| 9034822*PED | PRADAXAdabigatran etexilate mesylate | use | Jul 2031 |
| 8853156*PED | TRADJENTAlinagliptin | use | Sept 2031 |
| 10596120 | SYNJARDY XR, TRIJARDY XRempagliflozin; linagliptin; metformin hydrochloride; empagliflozin; metformin hydrochloride | product | Mar 2032 |
| Product | Exclusivity | Until |
|---|---|---|
| HERNEXEOSZONGERTINIB | NCE New chemical entity | Aug 2030 |
| JARDIANCEEMPAGLIFLOZIN | PED Paediatric | Dec 2026 |
| JASCAYDNERANDOMILAST | ODE-546 Orphan drug | Oct 2032 |
| JENTADUETOLINAGLIPTIN; METFORMIN HYDROCHLORIDE | PED Paediatric | Dec 2026 |
| JENTADUETO XRLINAGLIPTIN; METFORMIN HYDROCHLORIDE | PED Paediatric | Dec 2026 |
| OFEVNINTEDANIB ESYLATE | PED Paediatric | Mar 2027 |
| SYNJARDYEMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | PED Paediatric | Dec 2026 |
| SYNJARDY XREMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | PED Paediatric | Dec 2026 |
| TRADJENTALINAGLIPTIN | PED Paediatric | Dec 2026 |
Catalogue
Marketed products
127| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Adalimumab-adbm | Adalimumab-adbm | kit | 0597-0545BLA |
| Adalimumab-adbm | Adalimumab-adbm | kit | 0597-0555BLA |
| Adalimumab-adbm | Adalimumab-adbm | kit | 0597-0565BLA |
| Adalimumab-adbm | Adalimumab-adbm | kit | 0597-0575BLA |
| Adalimumab-adbm | Adalimumab-adbm | kit | 0597-0585BLA |
| Adalimumab-adbm | Adalimumab-adbm | kit | 0597-0595BLA |
| - | Aldesleukin | powder | 12714-213DRUG FOR FURTHER PROCESSING |
| - | Alemtuzumab | solution | 12714-085DRUG FOR FURTHER PROCESSING |
| - | Alemtuzumab | solution | 12714-089BULK INGREDIENT |
| - | Alemtuzumab | solution | 12714-210DRUG FOR FURTHER PROCESSING |
| - | Alemtuzumab | solution | 12714-211BULK INGREDIENT |
| - | Alteplase | solution | 12714-081BULK INGREDIENT |
| - | Alteplase | powder | 12714-082DRUG FOR FURTHER PROCESSING |
| - | Alteplase | powder | 12714-083DRUG FOR FURTHER PROCESSING |
| - | Atropine | powder | 12714-034BULK INGREDIENT |
| - | Atropine Sulfate | powder | 12714-031BULK INGREDIENT |
| Atrovent HFA | ipratropium bromide | aerosol, metered, respiratory (inhalation) | 0597-0087NDA |
| - | BUTYLSCOPOLAMINE BROMIDE | powder | 12714-011BULK INGREDIENT |
| Combivent Respimat | ipratropium bromide and albuterol | spray, metered, respiratory (inhalation) | 0597-0024NDA |
| Cyltezo | adalimumab-adbm | kit | 0597-0370BLA |
| Cyltezo | adalimumab-adbm | kit | 0597-0375BLA |
| Cyltezo | adalimumab-adbm | kit | 0597-0400BLA |
| Cyltezo | adalimumab-adbm | kit | 0597-0405BLA |
| Cyltezo | adalimumab-adbm | kit | 0597-0485BLA |
| Cyltezo | adalimumab-adbm | kit | 0597-0495BLA |
| - | Durvalumab | solution | 12714-087BULK INGREDIENT |
| - | Empagliflozin | powder | 12714-201BULK INGREDIENT |
| Gilotrif | afatinib | tablet, film coated, oral | 0597-0137NDA |
| Gilotrif | afatinib | tablet, film coated, oral | 0597-0138NDA |
| Gilotrif | afatinib | tablet, film coated, oral | 0597-0141NDA |
| Glyxambi | empagliflozin and linagliptin | tablet, film coated, oral | 0597-0164NDA |
| Glyxambi | empagliflozin and linagliptin | tablet, film coated, oral | 0597-0182NDA |
| HERNEXEOS | zongertinib | tablet, film coated, oral | 0597-9257NDA |
| - | Infliximab | solution | 12714-088BULK INGREDIENT |
| - | Interferon beta-1b | powder | 12714-084DRUG FOR FURTHER PROCESSING |
| - | Interferon-gamma1b | solution | 12714-080DRUG FOR FURTHER PROCESSING |
| JASCAYD | nerandomilast | tablet, film coated, oral | 0597-2465NDA |
| JASCAYD | nerandomilast | tablet, film coated, oral | 0597-7313NDA |
| Jardiance | Empagliflozin | tablet, film coated, oral | 0597-0152NDA |
| Jardiance | Empagliflozin | tablet, film coated, oral | 0597-0153NDA |
| - | Jardiance | powder | 12714-920DRUG FOR FURTHER PROCESSING |
| - | Jardiance | powder | 12714-930DRUG FOR FURTHER PROCESSING |
| Jentadueto | linagliptin and metformin hydrochloride | tablet, film coated, oral | 0597-0146NDA |
| Jentadueto | linagliptin and metformin hydrochloride | tablet, film coated, oral | 0597-0147NDA |
| Jentadueto | linagliptin and metformin hydrochloride | tablet, film coated, oral | 0597-0148NDA |
| Jentadueto XR | linagliptin and metformin hydrochloride | tablet, film coated, extended release, oral | 0597-0270NDA |
| Jentadueto XR | linagliptin and metformin hydrochloride | tablet, film coated, extended release, oral | 0597-0275NDA |
| Micardis HCT | telmisartan and hydrochlorothiazide | tablet, oral | 0597-0042NDA |
| Micardis HCT | telmisartan and hydrochlorothiazide | tablet, oral | 0597-0043NDA |
| Micardis HCT | telmisartan and hydrochlorothiazide | tablet, oral | 0597-0044NDA |
| - | Nerandomilast | tablet | 12714-122DRUG FOR FURTHER PROCESSING |
| - | Nerandomilast | powder | 12714-350BULK INGREDIENT |
| Ofev | nintedanib | capsule, oral | 0597-0143NDA |
| Ofev | nintedanib | capsule, oral | 0597-0145NDA |
| - | PHENYLEPHRINE HYDROCHLORIDE | powder | 12714-016BULK INGREDIENT |
| - | Palivizumab | solution | 12714-231DRUG FOR FURTHER PROCESSING |
| - | Palivizumab | solution | 12714-232DRUG FOR FURTHER PROCESSING |
| - | Pembrolizumab | solution | 12714-090DRUG FOR FURTHER PROCESSING |
| - | Pembrolizumab | liquid | 12714-091DRUG FOR FURTHER PROCESSING |
| Pradaxa | dabigatran etexilate mesylate | capsule, oral | 0597-0108NDA |
| Pradaxa | dabigatran etexilate mesylate | capsule, oral | 0597-0355NDA |
| Pradaxa | dabigatran etexilate mesylate | capsule, oral | 0597-0360NDA |
| Pradaxa | dabigatran etexilate | pellet, oral | 0597-0425NDA |
| Pradaxa | dabigatran etexilate | pellet, oral | 0597-0430NDA |
| Pradaxa | dabigatran etexilate | pellet, oral | 0597-0435NDA |
| Pradaxa | dabigatran etexilate | pellet, oral | 0597-0440NDA |
| Pradaxa | dabigatran etexilate | pellet, oral | 0597-0445NDA |
| Pradaxa | dabigatran etexilate | pellet, oral | 0597-0450NDA |
| Praxbind | idarucizumab | injection, intravenous | 0597-0197BLA |
| - | Risankizumbab | liquid | 12714-215BULK INGREDIENT |
| - | Risankizumbab | liquid | 12714-216BULK INGREDIENT |
| - | Risankizumbab | solution | 12714-217DRUG FOR FURTHER PROCESSING |
| - | Rituximab | solution | 12714-214BULK INGREDIENT |
| SPEVIGO | spesolimab-sbzo | injection, intravenous | 0597-0035BLA |
| SPEVIGO | spesolimab-sbzo | injection, intravenous | 0597-0620BLA |
| SPEVIGO | spesolimab-sbzo | injection, intravenous | 0597-7705BLA |
| Spiriva HandiHaler | TIOTROPIUM BROMIDE | capsule, oral, respiratory (inhalation) | 0597-0075NDA |
| Spiriva Respimat | tiotropium bromide inhalation spray | spray, metered, respiratory (inhalation) | 0597-0100NDA |
| Spiriva Respimat | tiotropium bromide inhalation spray | spray, metered, respiratory (inhalation) | 0597-0160NDA |
| Stiolto Respimat | tiotropium bromide and olodaterol | spray, metered, respiratory (inhalation) | 0597-0155NDA |
| Striverdi Respimat | olodaterol respimat inhalation spray | spray, metered, respiratory (inhalation) | 0597-0192NDA |
| Synjardy | empagliflozin and metformin hydrochloride | tablet, oral | 0597-0159NDA |
| Synjardy | empagliflozin and metformin hydrochloride | tablet, oral | 0597-0168NDA |
| Synjardy | empagliflozin and metformin hydrochloride | tablet, oral | 0597-0175NDA |
| Synjardy | empagliflozin and metformin hydrochloride | tablet, oral | 0597-0180NDA |
| - | Synjardy | tablet | 12714-902DRUG FOR FURTHER PROCESSING |
| - | Synjardy | tablet | 12714-903DRUG FOR FURTHER PROCESSING |
| - | Synjardy | tablet | 12714-904DRUG FOR FURTHER PROCESSING |
| - | Synjardy | tablet | 12714-906DRUG FOR FURTHER PROCESSING |
| Synjardy XR | empagliflozin, metformin hydrochloride | tablet, extended release, oral | 0597-0280NDA |
| Synjardy XR | empagliflozin, metformin hydrochloride | tablet, extended release, oral | 0597-0290NDA |
| Synjardy XR | empagliflozin, metformin hydrochloride | tablet, extended release, oral | 0597-0295NDA |
| Synjardy XR | empagliflozin, metformin hydrochloride | tablet, extended release, oral | 0597-0300NDA |
| - | Tafasitamab | powder | 12714-219DRUG FOR FURTHER PROCESSING |
| - | Telmisartan | granule | 12714-205DRUG FOR FURTHER PROCESSING |
| - | Tenecteplase | solution | 12714-233BULK INGREDIENT |
| - | Tenecteplase | powder, for solution | 12714-234DRUG FOR FURTHER PROCESSING |
| - | Tenecteplase | powder, for solution | 12714-236DRUG FOR FURTHER PROCESSING |
| - | Tipranavir | powder | 12714-901BULK INGREDIENT |
| Tradjenta | linagliptin | tablet, film coated, oral | 0597-0140NDA |
| - | Tremelimumab | solution | 12714-104BULK INGREDIENT |
| Trijardy XR | empagliflozin, linagliptin, metformin hydrochloride | tablet, extended release, oral | 0597-0380NDA |
| Trijardy XR | empagliflozin, linagliptin, metformin hydrochloride | tablet, extended release, oral | 0597-0385NDA |
| Trijardy XR | empagliflozin, linagliptin, metformin hydrochloride | tablet, extended release, oral | 0597-0390NDA |
| Trijardy XR | empagliflozin, linagliptin, metformin hydrochloride | tablet, extended release, oral | 0597-0395NDA |
| - | Zongertinib | tablet | 12714-128DRUG FOR FURTHER PROCESSING |
| - | Zongertinib | powder | 12714-301BULK INGREDIENT |
| - | dabigatran etexilate | powder | 12714-036BULK INGREDIENT |
| - | dabigatran etexilate | pellet | 12714-150DRUG FOR FURTHER PROCESSING |
| - | idarucizumab | liquid | 12714-195BULK INGREDIENT |
| - | idarucizumab | liquid | 12714-196DRUG FOR FURTHER PROCESSING |
| - | ipratropium bromide | powder | 12714-049BULK INGREDIENT |
| - | linagliptin | powder | 12714-153BULK INGREDIENT |
| - | linagliptin and metformin hydrochloride | tablet | 12714-801DRUG FOR FURTHER PROCESSING |
| - | linagliptin and metformin hydrochloride | tablet | 12714-802DRUG FOR FURTHER PROCESSING |
| - | nerandomilast | tablet | 12714-123DRUG FOR FURTHER PROCESSING |
| - | nintedanib esilate | powder | 12714-133BULK INGREDIENT |
| - | olodaterol | powder | 12714-916BULK INGREDIENT |
| - | palivizumab | solution | 12714-230BULK INGREDIENT |
| - | spesolimab | liquid | 12714-240BULK INGREDIENT |
| - | tafasitamab | solution | 12714-212BULK INGREDIENT |
| - | telmisartan | tablet | 12714-931DRUG FOR FURTHER PROCESSING |
| - | telmisartan | tablet | 12714-932DRUG FOR FURTHER PROCESSING |
| - | tiotropium bromide | powder | 12714-915BULK INGREDIENT |
| - | tislelizumab | liquid | 77657-010BULK INGREDIENT |
| - | tislelizumab | liquid | 77657-020DRUG FOR FURTHER PROCESSING |
| - | trastuzumab | solution | 12714-235BULK INGREDIENT |
Neighbours
Registered in the same town
12- WuXi Biologics Co., Ltd.Shanghai, CHN · 3 sites
- STA Pharmaceutical US LLCShanghai, CHN · 2 sites
- Shanghai Henlius Biopharmaceutical Co., Ltd.Shanghai, CHN · 2 sites
- Zencore Biologics Co., Ltd.Shanghai, CHN · 2 sites
- SGS North America Inc.Shanghai, CHN
- Baxter Healthcare CorporationShanghai, CHN
- Ajinomoto Health & Nutrition North America, Inc.Shanghai, CHN
- Taikun Pharmaceutical Technology IncShanghai, CHN
- Sinotherapeutics Inc.Shanghai, CHN
- YolTech (Nanjing) Therapeutics Co., Ltd.Shanghai, CHN
- El-Peptido (Shanghai) Biopharmaceutical Co., LtdShanghai, CHN
- Evereen Shanghai Biotechnology LtdShanghai, CHN
Compare
Comparable companies in Germany
- Beiersdorf AG3 sites · 107 NDC
- Merz Pharma GmbH & Co. KGaA3 sites · 17 NDC
- Bavarian Nordic A/S3 sites · 10 NDC
- Aesica Pharmaceuticals S.r.l.3 sites · 2 NDC
- BioNTech Manufacturing GmbH3 sites · 0 NDC
- Nuvisan France SARL3 sites · 0 NDC
- Corden Pharma International GmbH4 sites · 14 NDC
- Merck KGaA2 sites · 14 NDC
- Rentschler Biopharma SE2 sites · 8 NDC
- Symbiosis Pharmaceutical Services Limited2 sites · 3 NDC
Enquiry
Common questions
- Is Boehringer Ingelheim Biopharmaceuticals China Ltd FDA approved?
- Boehringer Ingelheim Biopharmaceuticals China Ltd holds 3 FDA-registered establishments across 2 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Boehringer Ingelheim Biopharmaceuticals China Ltd's drugs manufactured?
- At registered sites in China, Germany. The FDA register lists Shanghai; Biberach an der Riss; Ingelheim am Rhein. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
- What drugs does Boehringer Ingelheim Biopharmaceuticals China Ltd make?
- 127 products are listed under Boehringer Ingelheim Biopharmaceuticals China Ltd in the openFDA NDC Directory, most often as powder; solution; tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.